Tag: Stock Advisor

Now’s the Time to Buy These Stocks – Motley Fool
Stock News

Now’s the Time to Buy These Stocks – Motley Fool

A lot of investors -- maybe you're one of them -- are kicking themselves right now for not buying "wish list" companies when the stock market bottomed in March. Of course, timing the market is easy in hindsight and virtually impossible (not to mention extremely risky) in real time. But it's pointless to dwell on what's past. Instead, focus on the stocks that you can still buy today, at a significant discount to their prices at the beginning of the year. In fact, now is a great time to pick up shares of Waste Management (NYSE:WM), Brookfield Infrastructure Partners (NYSE:BIP), and Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B). Here's why.Image source: Getty Images.These three companies have a few things in common. First, they're all trading at l...
PLAY: 3 Investor Favorites for a “Re-Opening” Economy – StockNews.com
Stock News

PLAY: 3 Investor Favorites for a “Re-Opening” Economy – StockNews.com

As the U.S.—and the world for that matter—begins the reopening process, every business is trying to figure out what the new way of doing business looks like.We already know what the white collar version of post-pandemic business has become. It’s   gaming in between meetings and walking the dog.But what does business look like for the products and services we will again be engaging outside of our homes? That’s what companies are in the middle of working through as they gingerly reopen their doors, and get back to business.As investors we crave certainty, but to buy the stocks of many of these companies, we may have to trust in management to navigate the tricky reopening process. These are a few of the companies that, if they can successfully clear reopening hurdles, may reward patient...
Buy Alert: Novavax Stock Is Heading Higher – Nasdaq
Stock News

Buy Alert: Novavax Stock Is Heading Higher – Nasdaq

Novavax (NASDAQ: NVAX) has had a phenomenal run since I bought shares in the fall. Overall my cost basis is $6 per share; right now the stock is trading hands at $48 per share.What's fascinating, and a little scary, is that the dramatic stock increase has almost nothing to do with my original investment thesis. The reason why I bought Novavax: influenza. Novavax had a strong vaccine candidate in phase 3 trials, and the flu vaccine is a $5 billion market opportunity.What I didn't know at the time was that COVID-19 would strike, putting much of the world into lockdown mode, and sending some small biotech stocks into the stratosphere. That's why shares have run up so high: Novavax has developed a potential vaccine for COVID-19, and it's starting clinical trials in humans.Image So...
Stock Market in May: What Happened and Why? – Nasdaq
Stock News

Stock Market in May: What Happened and Why? – Nasdaq

The stock market had a rather strong month in May, with the S&P 500 rising by more than 6% on the heels of a very strong 18% rally in April.While the path higher hasn't been a straight one, and the volatility we've seen throughout the COVID-19 pandemic hasn't gone away, it's fair to say that investors seem far more optimistic than they did a couple of months ago.Image source: Getty Images. The stock market's performance in May Before we get into the major news of the month, here's a look at how the major stock indices performed:Index May 2020 Performance Year-to-Date ChangeS&P 500 6.5% (6.7%)Dow Jones Industrial Average 6.2% (11.7%)Nasdaq Composite 9.1% 4.6%Russell 2000 11.1% (16.1%)Data source: yCharts. Returns as of 5/29/2020 at approximately 2pm EDT...
Why Luckin Coffee Stock Surged 21.6% Wednesday – Motley Fool
Stock News

Why Luckin Coffee Stock Surged 21.6% Wednesday – Motley Fool

What happened Shares of Luckin Coffee (NASDAQ:LK) jumped more than 20% on Wednesday, continuing the stock's rally off its recent lows.  So what After being hit with an accounting scandal, executive terminations, and a Nasdaq delisting notice, Luckin Coffee's stock went on to suffer devasting losses of more than 95% from its all-time highs reached back in January.However, the Chinese coffeehouse chain's stock has rallied sharply off its lows of $1.33 on May 22 in recent days. Shares now fetch $2.59 after their gains on Wednesday. The reason for the rally? Rumors of asset sales and a potential buyout could be fueling the stock's recent ascent. Reuters reported on May 24 that restaurant giant Yum China and Tencent-baked Tim Hortons could be exploring the possibility of purc...
Stock Alert: Avis Budget Rises 12% – Nasdaq
Stock News

Stock Alert: Avis Budget Rises 12% – Nasdaq

(RTTNews) - Shares of Avis Budget Group Inc. (CAR) are climbing more than 12 percent or $2.02 in Tuesday's morning trade at $18.74 despite no stock-specific news. The stock has traded in a range of $6.35 to $52.98 in the past 52 weeks.Parsippany, New Jersey-based Avis Budget provides car and truck rentals, car sharing, and ancillary services to businesses and consumers.Avis Budget has said it expects a gradual recovery in revenues from June and improving thereafter, as shelter in place restrictions are lifted and leisure travel begins to resume. The company's current reservations show improvement in June and is expected to sequentially increase over the balance of the summer.Meanwhile, Avis' peer Hertz Global Holdings, Inc. (HTZ) said last Friday that it has filed for Chapter 11 reo...
Better Coronavirus Stock: Gilead Sciences or Vir Biotechnology? – Nasdaq
Stock News

Better Coronavirus Stock: Gilead Sciences or Vir Biotechnology? – Nasdaq

As the coronavirus outbreak continues to spread throughout the world, investors have been loading up on shares of companies working on treatment or prevention. Gilead Sciences (NASDAQ: GILD) rose as much as 29% this year, but has since given up some gains and is now up 11%. Vir Biotechnology (NASDAQ: VIR) stock has surged 170% in the same time.Gilead is the maker of remdesivir, the drug that recently received emergency use authorization from the U.S. Food and Drug Administration (FDA) for the treatment of severe coronavirus cases. Vir has partnered with pharma giant GlaxoSmithKline (NYSE: GSK) to pursue the discovery of antibodies to fight the coronavirus.Image source: Getty Images.If you're looking to bet on a coronavirus player now, you might be wondering which of ...